Metabolic surgery for type 2 diabetes mellitus |
| |
| Authors: | Jonathan Klonsky Michel M Murr |
| |
| Institution: | 1. Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec Heart and Lung Institute, Université Laval, 2725 Chemin Sainte-Foy, Québec City, Québec G1V-4G5, Canada;2. Cardiology Department, Expert Valve Center, Henri Mondor Hospital, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil 94000, France;3. INSERM Unit U955, Team 8, Paris-Est Creteil University, Val-de-Marne, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil 94000, France;1. School of Tourism Management, South China Normal University, Guangzhou, China;2. Key Laboratory of Brain, Cognition and Education Sciences (South China Normal University), Ministry of Education, China;3. School of Psychology, South China Normal University, Guangzhou, China;4. Foodservice and Lodging Department, Rosen College of Hospitality Management, University of Central Florida, Orlando, USA;5. School of Management, Jinan University, Guangzhou, China;1. Coventry University Business School, William Morris Building, 94 Gosford Street, Coventry CV1 5DL, UK;2. City University of London, London, UK |
| |
| Abstract: | Background: Metabolic surgery for morbid obesity induces significant weight loss and resolution of many obesity-related comorbidities, the most notable of which is remission of type 2 diabetes mellitus (DM). Such changes seem to precede significant weight loss in this population shortly after undergoing diversionary procedures.Objective: This article explores the evidence for salutary metabolic benefits of bariatric surgery, with special emphasis on glycemic control and remission of type 2 DM.Methods: We conducted a query of the PubMed database for articles published in English within the past 15 years using the search terms bariatric surgery, obesity, type 2 diabetes, gastric bypass, gastric banding, incretins, enteroinsular axis, GLP-1 (glucagon-like peptide-1), and GIP (glucose-dependent insulinotropic polypeptide). We targeted review articles as well as those discussing the effects of bariatric surgery on the enteroinsular axis and the respective effects on glyce-mic control.Results: Most of the clinical reports indicated a high remission rate (≥85%) for type 2 DM, and relatively higher rates in patients who underwent diversionary procedures. Studies with small cohorts and laboratory data suggested a role for gastrointestinal hormones in the regulation of glucose homeostasis after bariatric surgery.Conclusions: Gastrointestinal surgery for severe obesity, through restrictive and/or neurohormonal effects, is an effective treatment for type 2 DM. Surgically induced weight loss was found to be sustainable, durable, and associated with remission of type 2 DM, a reduction in mortality, and improvement in quality of life. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
